<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445575</url>
  </required_header>
  <id_info>
    <org_study_id>RBM 03-54</org_study_id>
    <secondary_id>AFSSAPS 060834</secondary_id>
    <nct_id>NCT00445575</nct_id>
  </id_info>
  <brief_title>Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone</brief_title>
  <acronym>PROFIDYS</acronym>
  <official_title>Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is intended to test the efficacy of an oral bisphosphonate (risedronate) to&#xD;
      decrease bone pain and improve radiological aspect in fibrous dysplasia of bone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In open pilot studies, it has been suggested that bisphosphonates may alleviate bone pain and&#xD;
      help decrease the surface of osteolytic lesion in patients with fibrous dysplasia of bone&#xD;
      (FD). So, in this randomized placebo controlled trial, we test the hypothesis that the&#xD;
      bisphosphonate risedronate reduces bone pain in patients with FD (study I, one year duration)&#xD;
      and decrease osteolytic lesions (study II, three years duration). Patients will take&#xD;
      risedronate during 2 months courses, every 6 months or a matching placebo. Dosage will be :&#xD;
      30mg tablet/day for adults and 5mg tablet x 2,4 according to the age and weight of the child.&#xD;
      All participants will receive calcium and vitamin D. All patients with renal phosphate&#xD;
      wasting will receive an oral phosphate supplement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2007</start_date>
  <completion_date type="Actual">December 7, 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of bone pain, assessed by visual analogical scale ranging from 0 to 10, on the most painful site.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Surface of osteolytic lesions at three years. Radiological improvement.</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of biochemical markers of bone turnover at three years</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of painful sites</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>one to three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in bone mineral density of the femoral neck at three years</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Fibrous Dysplasia of Bone</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment duration: 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment duration: 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>duration treatment: 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment duration: 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risedronate</intervention_name>
    <description>During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study I: patients with FD, with bone pain intensity above 3 on visual analogical scale&#xD;
             from 0 to 10&#xD;
&#xD;
          -  Study II: patients with FD with at least one osteolytic lesion and no current bone&#xD;
             pain&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients &lt; 8 years old&#xD;
&#xD;
          -  other diseases affecting bone metabolism&#xD;
&#xD;
          -  patients with malignant diseases or other conditions likely to reduce their life&#xD;
             expectancy to less than 3 years&#xD;
&#xD;
          -  patients with history of significant upper gastrointestinal disorders&#xD;
&#xD;
          -  renal failure (creatinine clearance &lt; 25 ml/mn)&#xD;
&#xD;
          -  severe liver disease&#xD;
&#xD;
          -  history of iritis or uveitis&#xD;
&#xD;
          -  rickets or osteomalacia&#xD;
&#xD;
          -  allergy to bisphosphonates&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  prior treatment with a bisphosphonate&#xD;
&#xD;
          -  laboratory abnormalities that may be considered as clinically significant by trial&#xD;
             physicians&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROLAND D CHAPURLAT, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE ORCEL, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOPITAL LARIBOISIERE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SOCRATES D PAPAPOULOS, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital E Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cologne Clinical Centre</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heildeberg Clinical Centre</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.dysplasie-fibreuse-des-os.info/fr/accueil.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 8, 2007</study_first_submitted>
  <study_first_submitted_qc>March 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fibrous dysplasia of bone</keyword>
  <keyword>Mac Cune Albright syndrome</keyword>
  <keyword>bisphosphonates</keyword>
  <keyword>risedronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrous Dysplasia of Bone</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

